je.st
news
H3 Biomedicine Receives FDA Acceptance For Investigational New Drug Application
2016-06-01 06:06:14| drugdiscoveryonline Home Page
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of the Eisai Group, announced recently that the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application to begin Phase 1 clinical trials for its lead oncology drug candidate H3B-8800
Tags: application
drug
acceptance
receives
Category:Biotechnology and Pharmaceuticals